Peptide therapies surge in popularity as celebrities and influencers promote them for longevity and vitality. GLP-1 medications, synthetic peptides for obesity treatment, have reached nearly 10 million American users with significant retail revenue growth. However, experts warn caution. While some peptide therapies undergo rigorous clinical trials, many marketed online lack proper vetting, dosing consistency, and efficacy data. Side effects remain poorly understood across diverse populations. Even well-tested GLP-1 drugs cause severe complications including pancreatitis and gallbladder issues in some users. The peptide market boom presents both opportunity and risk for consumers and investors alike.
Post from MarketNews_en
Log in to interact with content.